Mark A. Stacy, MD
Department / Division
Medicine /
Medicine-Neurology
Address
DUMC 3333
Durham, NC 27710
Appointment Telephone
919-668-7600
Office Telephone
919-668-2493
Fax Telephone
919-681-4935
- MD, University of Missouri Columbia School of Medicine, 1986
- Neurology, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1990
- Movement Disorders, Baylor College of Medicine (Texas), 1991
Clinical Interests
Movement disorders; Parkinson's disease and other Parkinsonian disorders; generalized and focal dystonias; Lewy body disease; myoclonus; restless legs syndrome; progressive supranuclear palsy; corticobasal ganglionic degeneration; multiple-system atrophy; Shy-Drager syndrome; spasmodic torticollis; tremor and tic disorders; botulinum toxin injections; deep brain stimulation
Research Interests
Mark Stacy has clinical trial efforts concentrated on Neuroprotective and Neuro-regenerative therapies in PD, and developing biomarkers for early diagnosis in PD. He has extensive experience with Glial Derived Neurotrophic Factor (GDNF), neuroimmunophyllins (GPI-1046, AMG-474), jnk inhibitors (CEP-1347, TCH-346), and viral vectors (Ceregene). His independent research interests in Parkinson’s disease include motor and non-motor symptoms of wearing off, and pathological gambling and other impulse control disorders. He has published more than 100 manuscripts in the areas of PD, dystonia, tremor and other movement disorders. He is also the editor of The Handbook of Dystonia.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Actelion
- Allergan, Inc.
- Avanir Pharmaceuticals
- Clinipace
- Emd Serono Inc. (Merck KGaA,Germany-Not Merck USA)
- General Electric Company
- Lundbeck
- Michael J Fox Foundation
- Neurologix, Inc.
- Novartis
- Osmotica
- Schering-Plough Corp. (owned by Merck & Co, USA)
- Synosia Therapeutics
- Taylor and Francis Group (Informa)
- Teva Neuroscience
- University of South Florida Health Professionals
- Wake Forest University School of Medicine
